Testicular cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto PiliBruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, Jue Wang

Research output: Contribution to journalReview articlepeer-review

98 Scopus citations


An estimated 8090 new cases of testicular cancer were diagnosed in the United States in 2008. Although relatively uncommon overall, germ cell tumors (GCTs) constitute the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure. Updates to the 2009 NCCN Guidelines include the addition of doses for single-agent carboplatin for seminoma and changes to category 1 for recommendations on radiotherapy and surveillance.

Original languageEnglish (US)
Pages (from-to)672-693
Number of pages22
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number6
StatePublished - Jun 2009


  • Alpha-fetoprotein
  • Cisplatin
  • Germ cell tumors
  • Human chorionic gonadotropin
  • Lactate dehydrogenase
  • NCCN Clinical Practice Guidelines
  • Nonseminoma
  • Seminoma
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Testicular cancer'. Together they form a unique fingerprint.

Cite this